Penetration testing is a simulated attack that tries to prove whether weaknesses can actually be exploited, while routine vulnerability scanning mainly identifies known issues and exposures. In healthcare M&A, that distinction matters because leaders need evidence about real risk across merged systems, not just a list of findings. Effective testing helps prioritize remediation, compliance review, and integration decisions before the deal closes.
Why the distinction matters in healthcare M&A
In healthcare mergers and acquisitions, the difference is not academic. Vulnerability scanning tells you what is known and exposed, while penetration testing shows whether a weakness can actually be turned into access, lateral movement, or data exposure across interconnected environments. That matters when deal teams are deciding whether a risk is a cleanup item, a closing condition, or a reason to slow integration.
Scans are useful for breadth and cadence, especially when you need a repeatable inventory of known issues across many systems. Pen tests are narrower, but they answer a different question: what can a real attacker do if merged networks, legacy platforms, third-party links, or shared trust paths are present?
For healthcare transactions, the practical difference is that a scan may identify an outdated component, but a pen test can demonstrate whether that component sits on a path to protected health data, operational technology, revenue-cycle systems, or identity infrastructure that would increase the blast radius of compromise.
How each method is used in due diligence and integration planning
A routine OWASP Web Security Testing Guide style scan is best treated as a baseline hygiene activity: it supports discovery, triage, and remediation tracking. It is valuable when the question is, “What should we fix?”
Penetration testing is the better tool when the question is, “What is the realistic business impact if someone chains these weaknesses together?” In an M&A context, that usually means validating high-value paths such as externally reachable applications, exposed administrative interfaces, directory trust relationships, and systems that bridge the target and acquirer environments.
Leaders often need both outputs, but for different decisions. Scanning supports volume and coverage. Pen testing supports prioritisation, deal risk discussion, and integration sequencing, because it helps distinguish theoretical exposure from evidence-backed exploitability.
If the diligence team is using security findings to decide what can safely connect on day one, testing should focus on the highest-value systems first. That is where a single proven exploit path can matter more than dozens of lower-severity findings.
What practitioners should watch for in healthcare deals
Healthcare deals frequently combine large attack surfaces, regulated data, and inherited technical debt. A useful NHI Lifecycle Management Guide lens is to look for inherited access paths, stale credentials, and overextended trust relationships that scanners may list but cannot prove in use. In practice, the meaningful question is whether those paths still work, still matter, and still reach sensitive systems.
What to verify: whether findings are being interpreted by exploit path, not by count alone. A high scan total can look alarming, but a smaller set of exploitable weaknesses may be the real deal issue if they connect to ePHI, administrative control planes, or shared identity stores.
What practitioners underestimate: post-merger connectivity changes the answer. A weakness that is low-risk in a standalone environment can become material once trust, routing, federation, or shared administration is introduced during integration.
Practitioner takeaway: Use scanning for breadth and pen testing for proof. In healthcare M&A, the decision-making value comes from knowing which findings are exploitable in the merged reality, not just which weaknesses exist on paper.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
OWASP Agentic AI Top 10 and OWASP Non-Human Identity Top 10 address the attack and risk surface, while CIS Controls v8 and NIST CSF 2.0 set the governance and control requirements practitioners need to meet.
| Framework | Control / Reference | Relevance |
|---|---|---|
| OWASP Agentic AI Top 10 | A3 — Tool and Action Misuse | Pen testing and exploit validation depend on controlling how tools or actions are used. |
| Recommendation — Validate tool actions to prevent misuse during security testing and integration. | ||
| CIS Controls v8 | CIS 7 — Continuous Vulnerability Management | The contrast hinges on scanning for known issues versus validating exploitability. |
| CIS 18 — Penetration Testing | Directly addresses simulated attack testing to prove real-world exploitability. | |
| Recommendation — Run continuous vulnerability management to inventory, prioritise and track known exposures. Perform penetration testing to verify whether weaknesses can be exploited in practice. | ||
| OWASP Non-Human Identity Top 10 | NHI-02 — Credential and Secret Lifecycle | Healthcare M&A often inherits access paths that must be tested and retired safely. |
| Recommendation — Inventory, rotate and revoke inherited credentials before integration expands exposure. | ||
| NIST CSF 2.0 | PR.DS — Data Security | The issue is whether merged weaknesses could expose regulated healthcare data. |
| Recommendation — Protect sensitive data paths and verify exposure through evidence-based testing. | ||
Related resources from NHI Mgmt Group
- What is the difference between vulnerability scanning and penetration testing in practice?
- What is the difference between automated vulnerability scanning and human-based penetration testing?
- What is the difference between autonomous testing and traditional vulnerability scanning?
- What is the difference between API security scanning and penetration testing?
